6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d] azepine | 847199-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d] azepine
• 英文别名: 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine；7-chloro-N-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-6-amine
• CAS: 847199-03-5
• 化学式: C₁₂H₁₄ClF₃N₂
• 分子量: 278.705
• InChiKey: WBGGNEYAISWPRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d] azepine 、 丁二酸 以 异丙醇 为溶剂， 反应 66.0h， 以to give seed crystals of 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine succinic acid salt (230 mg, 81% yield)的产率得到7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine succinic acid salt
  参考文献：
  名称：

  6-(2,2,2-Trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist

  摘要：

  本发明提供了式（I）的7-氯-6-（2,2,2-三氟乙基氨基）-2,3,4,5-四氢-1H-苯并[d]氮杂环或其药学上可接受的盐，并将其用作选择性5-HT2c激动剂，用于治疗与5-HT2c相关的疾病，包括肥胖症、强迫症、焦虑症和抑郁症。

  公开号：

  US20060264418A1
• 作为产物：
  描述：

  7-chloro-3-(2,2,2-trifluoroacetyl)-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d] azepine
  参考文献：
  名称：

  [EN] 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST
  [FR] 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINE UTILISEE COMME AGONISTE DU RECEPTEUR 5-HT2C

  摘要：

  本发明提供了一种式(I)的7-氯-6-(2,2,2-三氟乙基氨基)-2,3,4,5-四氢-1H-苯并[d]氮杂环己烯，或其药学上可接受的盐，并且其用作选择性5-HT2c激动剂，用于治疗与5-HT2c相关的疾病，包括肥胖症、强迫/强迫症、焦虑和抑郁症。

  公开号：

  WO2005019180A1

文献信息

• 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080214520A1

  公开（公告）日：2008-09-04

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R 6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

  本发明提供了Formula I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：Formula (I)其中：R6选自(a、b、c、d、e)等基团组成的群，其他取代基如规范中定义。
• 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists
  申请人：Allen John Gordon

  公开号：US20080207897A1

  公开（公告）日：2008-08-28

  The present invention provides 6-substituted 2,3,4,5-tetrahydro- 1 H-benzo[d]azepines of Formula (I) as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R 6 is —C≡C—R 10 , —CH═CR 11 R 11′ , or —(C 0 -C 8 )alkyl-Ar 2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.

  本发明提供了式（I）的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中R6为—C≡C—R10，—CH═CR11R11′，或—(C0-C8)烷基-Ar2，烷基上可选地带有1至6个氟取代基，其他取代基在规范中定义。
• 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
  申请人：Allen John Gordon

  公开号：US20080255092A1

  公开（公告）日：2008-10-16

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.

  本发明提供了公式（I）的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：R6为—（CrC3）烷基-S—（C0-C3）烷基-R10，—（C1-C3）烷基-NR11R12，—（CrC3）烷基-O—R13，其他取代基如规范中所定义。
• 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080269196A1

  公开（公告）日：2008-10-30

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了式（I）的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2c受体激动剂，用于治疗与5-HT2c相关的疾病，包括肥胖、强迫症/强迫性障碍、抑郁症和焦虑症，其中，R6为—NR10R11，其中R10为取代的苯基烷基或取代的吡啶基烷基，其他取代基如说明书所定义。
• 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：BRINER Karin

  公开号：US20110269745A1

  公开（公告）日：2011-11-03

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，其化学式为(I)，作为选择性5-HT2c受体激动剂，用于治疗5-HT2c相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症，其中，R6是—NR10R11，其中R10是取代的苯基烷基或取代的吡啶基烷基，其他取代基如规范中所定义。